The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies.

Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and almost 41,300 employees. Since it was founded in 1885, the privately-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Boehringer Ingelheim set up its China branch office in March 1994. A year later, Boehringer Ingelheim International Trade (Shanghai) Co., Ltd. was registered. In December 1995, Boehringer Ingelheim Shanghai Pharmaceuticals Ltd. was established. The total investment amounts to 29 Million US$ marking the beginning of the company's continuous investment in China. In 2002, the company set up its production plant in Shanghai Zhangjiang High-tech Park. It has introduced state-of-art manufacturing facility with design, equipment and management standard that are on a par with those in the plants of other countries. The plant production strictly follows the international GMP standard. Currently the company has offices in Shanghai, Beijing, Guangzhou, Chengdu, Hangzhou and Nanjing with over 1000 employees.

Boehringer Ingelheim's business in China is focusing on prescription medicines, consumer healthcare , animal health and international procurement, covering major markets in the country. The company spares no effort in bringing innovative pharmaceutical products to China market, and as a result, Boehringer Ingelheim has obtained a strong recognition for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines.
 

Contact us:

Boehringer Ingelheim Shanghai Pharmaceuticals Co.,Ltd.
Add.: 22F, No.138 Pudong Avenue
Shanghai 200120, P.R.China
Tel: +86 21 5888 2200
Fax:+86 21 5878 1100